Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Objectives:
- Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with
placebo, on the quantitative progression of atherosclerosis as assessed by carotid
artery intima-media thickness (CIMT)
- Secondary: To evaluate the safety and tolerability of the above rimonabant regimen in
the study population of atherosclerosis patients.